Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 14/20 | 0.73 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.70 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.70 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.58 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468155 | 0.86 | KCNN3 (0.55) | KCNN3KCNN1KCNN2PDE10AKDM4E | |
| SCHEMBL5456353 | 0.83 | KCNN3 (0.52) | KCNN3KCNN1KCNN2KDM4E | |
| SCHEMBL5449849 | 0.83 | KCNN3 (0.52) | KCNN3KCNN1KCNN2PDE10AKDM4E | |
| SCHEMBL5453724 | 0.83 | KCNN3 (0.70) | KCNN3KCNN1KCNN2PDE10A | |
| SCHEMBL13117302 | 0.83 | KCNN3 (0.80) | KCNN3KCNN1KCNN2PDE10A | |
| SCHEMBL5456522 | 0.81 | CDK2 (0.63) | KCNN3KCNN1KCNN2KDM4E | |
| SCHEMBL5452944 | 0.80 | TP53 (0.61) | KCNN3KDM4E | |
| SCHEMBL13985944 | 0.80 | KCNN3 (0.77) | KCNN3KCNN1KCNN2PDE10A | |
| SCHEMBL5458441 | 0.80 | KCNN3 (0.48) | KCNN3KCNN1KCNN2KDM4E | |
| SCHEMBL5463452 | 0.79 | CDK2 (0.61) | KCNN3KCNN1KCNN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | claimed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | claimed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | JUN, CHUK, RELA | KCNN3 3885/4885KCNN1 3422/4885KCNN2 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.